Remission endpoints in ulcerative colitis: A systematic review

Table 6 Clinical studies measured with the ulcerative colitis endoscopic index of severity

Ref.	Year	Type of study	Drug/subject of study	Entry criteria	Primary endpoint	Secondary endpoint	Remission/clinical improvement	Length of study
Hartman et al[54]	2016	Randomised, double-blind, placebo-controlled study	AVX-470, oral	36 patients with Mayo score 5-12 and Mayo ES ≥ 2	Not set, but implies clinical response at week 4	Not set	Remission was not defined. Clinical response Mayo reduction ≥ 3	4 wk
Lin et al[55]	2015	Prospective, multi-centre study	Faecal calprotectin	52 patients with UC	N/A	N/A	Endoscopic remission: UCEIS < 3	N/A
Magro et al[56] ACERTIVE study	2016	Cross-sectional multi-centre study	Faecal calprotectin/ lipocalin	371 patients Mayo partial score < 2, montreal classification < 2			Remission: UCEIS ≤ 1 Mucosal healing: Mayo ES = 0

UCEIS: Ulcerative colitis endoscopic index of severity; UC: Ulcerative colitis; ES: Endoscopic subscore; N/A: Not available.